DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Tumour Biol. 2016 Jun;37(6):7059-73. doi: 10.1007/s13277-016-5005-2. Epub 2016 Mar 4.

Abstract

Dipeptidyl peptidase IV (DPPIV/CD26) is a multifunctional protein with intrinsic peptidase activity that inactivates or degrades some bioactive peptides. It is the main cellular binding protein for ecto-adenosine deaminase and interacts with extracellular matrix proteins, besides participating in different signaling pathways. Due to these multiple functions, DPPIV/CD26 has been shown to be closely related to the tumor process. It has been reported that the progression of certain types of cancer is accompanied by a decrease in DPPIV/CD26 expression, and studies have shown that the malignant phenotype can be reverted when DPPIV/CD26 expression is induced in these cancer cells, characterizing this protein as a tumor suppressor. On the other hand, DPPIV/CD26 was described as a protein associated with invasion and metastatic spread, characterizing it as a marker of malignancy. Thus, this review explores the roles of DPPIV/CD26 expression in tumor progression in different types of cancer and demonstrates the importance of this protein as a promising therapeutic target and tumor biomarker.

Keywords: Biomarker; CD26; DPPIV; Marker of malignancy; Therapeutic target; Tumor suppressor.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism*
  • Dipeptidyl Peptidase 4 / metabolism*
  • Genes, Tumor Suppressor*
  • Humans
  • Neoplasms / diagnosis*
  • Neoplasms / metabolism*

Substances

  • Biomarkers
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4